Monopar Therapeutics Inc (MNPR)

Monopar Therapeutics Inc (MNPR) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $498M; returns 1 day -2.7%, 1 week +2.0%, 1 year -13.1%.

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company primarily focused on developing advanced oncology therapies and treatments for rare genetic diseases. As of early 2026, the company's business model is centered on a high-value development pipeline with zero product sales revenue, supported by a significant cash runway following a $135 million capital raise in late 2025.

Groups MNPR belongs to

• Buying Back Stock
• Clinical Stage Biotech
• Biotechnology
• Oncology
• Rare Diseases
• Clinical Stage Biopharma
• Healthcare
• Biopharmaceutical
• Precision Medicine
• Life Sciences
• Pharmaceuticals

MNPR financial model: income statement, cash flow and balance sheet